Answers are grounded in this paper and cite their sources.
Case series reveals rapid resolution of haemolysis with tocilizumab in sickle cell disease patients, suggesting a new treatment avenue.
Background and Objectives Hyperhaemolysis syndrome is a life‐threatening complication of transfusion, potentially triggered by macrophage activation, with limited treatment options. Tocilizumab, an anti‐IL6 monoclonal antibody, has mechanistic rationale for use and has been shown to be effective in a small number of cases. In this paper, we review four cases of hyperhaemolysis treated with tocilizumab in the context of the existing literature. Materials and Methods Cases of use of tocilizumab in hyperhaemolysis were identified from two large specialist haemoglobinopathy centres between the period January 2021 and March 2025. Clinical and laboratory data were collected. Results Four cases of hyperhaemolysis treated with IVIG, steroids and tocilizumab were reported. In all cases, haemolysis responded rapidly to tocilizumab therapy. Two patients subsequently received RBC transfusions without haemolysis; two patients died from causes unrelated to haemolysis. Conclusions This case series supports the use of tocilizumab as a therapeutic option for rapid resolution of haemolysis. It is generally widely available and should be considered a suitable and cost‐effective alternative to currently available options.
No takes yet. Share an insight, caveat, or question.
Wolf et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: